With a 40% gain up for grabs within the next six
months, you can't afford to miss this “pillar of profits” by Andrew Snyder D Y N A M I C   W E A L T H Genzyme, which is developing clo-
farabine with the company, could
offer to buy out Bioenvision. And
although that's just a rumor right
now, I believe that even if there was
no hint of a buyout, following the
possible approval of clofarabine, a
merger between the two companies
would make perfect sense. And even
if it never happens, this US$7.66 stock
could easily see US$15 in the near
term on drug approval alone.       IbelievethatBioenvision'sstrong
performancethroughoutDecember
couldbethestartofaruntoatleast
US$15 near term. Buy Bioenvision (BIVN:NAS- DAQ) under US$8.50. ¦       One of the most popular trading
philosophies — particularly for more
novice investors — is to buy a com-
pany whose business you under-
stand or whose product you use on a
regular basis. After all, if you use a
product on a daily basis, there's a
pretty good chance that plenty of
other people do too. And where there
is big demand, there is bound to be
big profits.       Two products I use on a daily
basis are my cell phone and com-
puter. After all, I am writing this on  a computer and my phone is lying
within arm's reach. There are millions
of people across the globe who are
also dependent on this technology.
One thing is sure: Worldwide demand
for these products is not
going down anytime soon.       With that in mind, you'd think
finding a profitable investment cen- tered on cell phone and computer
technology would be an easy task.
Unfortunately, it's not. The winners
and losers in the two industries con-
stantly ebb and flow as consumer
trends change and evolve. Picking a
long-term winner is hard to do. But
thanks to my “five pillars of profits”
approach, I've uncovered a company
poised to do well no matter what
consumers are up to.      Flextronics International
(FLEX:NASDAQ) is the world's largest electronics manufacturer and
assembler. It designs and manufac-
tures computers for many of the
world's top brands. It's the only com-
pany in its industry that stood up to
my rigorous criteria. “Five pillars of profits” So what are my “five pillars of profits” grading criteria? Well, basi- cally, when evaluating an investment,
I look at five distinct aspects of a com-
pany. They are: the company's indus-
try, its products, its fundamentals, its
technical indicators, and the invest-
ment's overall risk. If a company has
what it takes to make the grade in all
five areas, it is worthy of your portfo-
lio. If not, I put it aside until it can.       And here's why Flextronics
passed the test with flying colors:       The first thing that caught my eye
was its industry. Very few name-brand
computer companies assemble or
even design their products. Names
like Hewlett Packard and Motorola
look to Flextronics to assemble and
design their products. So no matter
who is leading the industry, Flex-
tronics will grab a large and profitable
share of their business.       Another aspect of the electronics
manufacturing industry is its substan-             

Next page... 2